Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Aug;10(Suppl 21):S2522-S2536.
doi: 10.21037/jtd.2017.12.50.

Reirradiation for locoregionally recurrent non-small cell lung cancer

Melissa A L Vyfhuis  1 , Stephanie Rice  1 , Jill Remick  1 , Sina Mossahebi  1 , Shahed Badiyan  1 , Pranshu Mohindra  1 , Charles B Simone 2nd  1
Affiliations
Review

Reirradiation for locoregionally recurrent non-small cell lung cancer

Melissa A L Vyfhuis et al. J Thorac Dis. 2018 Aug.

Abstract

Locoregional failure in non-small cell lung cancer (NSCLC) remains high, and the management for recurrent disease in the setting of prior radiotherapy is difficult. Retreatment options such as surgery or systemic therapy are typically limited or frequently result in suboptimal outcomes. Reirradiation (reRT) of thoracic malignancies may be an optimal strategy for providing definitive local control and offering a new chance of cure. Yet, retreatment with radiation therapy can be challenging for fear of excessive toxicities and the inability to safely deliver definitive (≥60 Gy) doses of reRT. However, with recent improvements in radiation delivery techniques and image-guidance, dose-escalation with reRT is possible and outcomes are encouraging. Here, we present a review of various radiation techniques, clinical outcomes and associated toxicities in patients with locoregionally recurrent NSCLC treated primarily with reRT.

Keywords: Reirradiation (reRT); intensity modulated radiation therapy (IMRT); non-small cell lung cancer (NSCLC); proton beam therapy (PBT); stereotactic body radiation therapy (SBRT).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

References

    1. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin 2017;67:7-30. 10.3322/caac.21387 - DOI - PubMed
    1. Goldstraw P, Chansky K, Crowley J, et al. The IASLC lung cancer staging project: Proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM Classification for lung cancer. J Thorac Oncol 2016;11:39-51. 10.1016/j.jtho.2015.09.009 - DOI - PubMed
    1. Albain KS, Swann RS, Rusch VW, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 2009;374:379-86. 10.1016/S0140-6736(09)60737-6 - DOI - PMC - PubMed
    1. Aupérin A, Le Pechoux C, Rolland E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non - small-cell lung cancer. J Clin Oncol 2010;28:2181-90. 10.1200/JCO.2009.26.2543 - DOI - PubMed
    1. Bradley JD, Paulus R, Komaki R, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage 3 NSCLC RTOG 0617 - Bradley Lancet 2015. Lancet Oncol 2015;16:187-99. 10.1016/S1470-2045(14)71207-0 - DOI - PMC - PubMed

LinkOut - more resources